AstraZeneca Email Format
Pharmaceutical Manufacturing
・
50,001-100,000 employees
・
Cambridge, England, UK
AstraZeneca is a global biopharmaceutical company that discovers, develops, and commercializes prescription medicines for oncology, cardiovascular, renal, metabolic, respiratory, and immunology therapeutic areas.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@astrazeneca.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
1999
Headquarters
Cambridge, England, UK
Revenue
$25B-$50B
FUNDING Stage
Public
Website
Key Executives
Pascal Soriot (Executive Director and Chief Executive Officer), Aradhana Sarin (Chief Financial Officer), Pam Cheng (Executive Vice President, Global Operations, IT & Chief Sustainability Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of AstraZeneca?
AstraZeneca uses the first.last format, so Jane Smith would be jane.smith@astrazeneca.com.
What are AstraZeneca's main therapy areas?
AstraZeneca focuses on three core areas: Oncology, BioPharmaceuticals (which covers Cardiovascular, Renal and Metabolism, Respiratory and Immunology, and Infectious Disease), and Rare Disease, the latter delivered through its Alexion division.
How does AstraZeneca's Oncology Business Unit approach cancer treatment?
AstraZeneca's Oncology Business Unit, led by David Fredrickson, develops and commercialises medicines including Tagrisso for lung cancer and Lynparza for multiple tumour types, with over 85 abstracts presented at ASCO 2026 spanning liver, breast, and bladder cancers.
Who leads AstraZeneca and where is the company headquartered?
Pascal Soriot serves as AstraZeneca's Executive Director and CEO, a role he has held since October 2012. The company is headquartered in Cambridge, England, UK, and employs around 79,352 people worldwide.
Does Alexion, AstraZeneca Rare Disease operate as a separate division?
Yes, Alexion operates as AstraZeneca's dedicated rare disease division following AstraZeneca's $39 billion acquisition of Alexion in 2021. Marc Dunoyer serves as CEO of Alexion and Chief Strategy Officer of AstraZeneca. Tools like Clay can help you find and verify specific Alexion contacts for outreach.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating